Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database

Abstract Background The incidence of pediatric inflammatory bowel disease (IBD) significantly increased recently. Infliximab (IFX) and adalimumab (ADA), both TNF-α inhibitors, are the only FDA-approved treatments for pediatric IBD. Due to the unique physiological and developmental characteristics of...

Full description

Bibliographic Details
Published in:	BMC Gastroenterology
Main Authors:	Yanhong Deng, Shengying Shi, Senling Feng, Xiangping Tan, Yinling Wang, Jinjin Yin, Shaozhi Liu, Yuanmei Gao
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Subjects:	Infliximab Adalimumab Adverse event Pharmacovigilance Pediatric Inflammatory bowel diseases
Online Access:	https://doi.org/10.1186/s12876-025-04154-w

Similar Items

Safety profile and side effects of infliximab and adalimumab in inflammatory bowel disease at a referral center in northeastern Brazil
by: Joelma Aurélio de Sousa Santos, et al.
Published: (2024-02-01)

Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
by: Tatyana Valentinovna Mezenova, et al.
Published: (2012-04-01)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
by: Yoon Suk Jung, et al.
Published: (2021-01-01)

Comparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis
by: Muhammed B. Durak, et al.
Published: (2025-01-01)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
by: Zvonimir Petric, et al.
Published: (2022-08-01)

Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis
by: Weishai Liu, et al.
Published: (2023-05-01)

Effect of Infliximab and Adalimumab on Experimental Colitis Following Orally Supplemented Iron
by: John Triantafillidis, et al.
Published: (2017-01-01)

Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients
by: Akpedje Serena Dossou, et al.
Published: (2025-09-01)

Comparison Between Adalimumab and Infliximab in Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis
by: Tarek Aboursheid, et al.
Published: (2025-01-01)

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA
by: Francisco José Toja-Camba, et al.
Published: (2023-11-01)

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
by: M Rodgers, et al.
Published: (2011-02-01)

Thrombotic adverse events associated with TNF-alpha blockers: a real-world pharmacovigilance analysis of the FAERS database
by: Lijuan Song, et al.
Published: (2025-04-01)

A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database
by: Feifei Wang, et al.
Published: (2025-07-01)

Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
by: Yong Il Lee, et al.
Published: (2021-03-01)

Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
by: Xianyu Dai, et al.
Published: (2025-07-01)

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
by: Wenting Zhang, et al.
Published: (2024-08-01)

Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
by: Paula Zapata-Cobo, et al.
Published: (2023-10-01)

Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges
by: Stefania Cheli, et al.
Published: (2023-06-01)

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
by: Sara Salvador-Martín, et al.
Published: (2021-10-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Safety profile of anti-tumor necrosis factor therapy in inflammatory bowel disease – a single center experience
by: Piotr Eder, et al.
Published: (2015-09-01)

Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database
by: Qian Qiao, et al.
Published: (2025-01-01)

Pregnancy Recommendations Solely Based on Preclinical Evidence Should Be Integrated with Real-World Evidence: A Disproportionality Analysis of Certolizumab and Other TNF-Alpha Inhibitors Used in Pregnant Patients with Psoriasis
by: Mario Gaio, et al.
Published: (2024-07-01)

Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database
by: Zhifang Wang, et al.
Published: (2025-07-01)

Design of an Array to Evaluate Biomarkers of Response to Biological Treatments in Inflammatory Bowel Disease
by: Andrea Rodríguez-Lopez, et al.
Published: (2025-07-01)

Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
by: Rita Lauro, et al.
Published: (2021-11-01)

Risk assessment of the top 50 drugs associated with drug-induced orthostatic hypotension: a disproportionality analysis of the FAERS and JADER databases
by: Gaocan Ren, et al.
Published: (2025-03-01)

A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database
by: Shichao Cui, et al.
Published: (2024-07-01)

Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future
by: Manish Manrai, et al.
Published: (2024-03-01)

Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease Patients
by: Michelangelo Rottura, et al.
Published: (2025-03-01)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
by: Giammarco Mocci, et al.
Published: (2022-07-01)

The total gut mucosal and fecal bacterial load increases in successful treatment of inflammatory bowel disease with infliximab
by: Rebecka Ventin-Holmberg, et al.
Published: (2025-08-01)

Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs
by: Anna Pau, et al.
Published: (2025-01-01)

Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives
by: Gerardo Cazzato, et al.
Published: (2021-08-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database
by: Shuang Xia, et al.
Published: (2024-01-01)

Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024
by: Siyu Lou, et al.
Published: (2025-06-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
by: Silvia Marquez-Megias, et al.
Published: (2022-05-01)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
by: So Yoon Choi, et al.
Published: (2019-09-01)